Patents by Inventor Patrick Tielmann

Patrick Tielmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process and intermediates for the production of CCR2 antagonists
    Patent number: 9067951
    Abstract: The present invention relates to a process for the production of novel antagonists for CCR2 (CC chemokine receptor 2) and intermediates thereof.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: June 30, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Christoph Hoenke, Thomas Trieselmann, Patrick Tielmann
  • PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS
    Publication number: 20140336374
    Abstract: The present invention relates to a process for the production of novel antagonists for CCR2 (CC chemokine receptor 2) and intermediates thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heiner EBEL, Sara FRATTINI, Riccardo GIOVANNINI, Christoph HOENKE, Thomas TRIESELMANN, Patrick TIELMANN
  • Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
    Patent number: 8835440
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: September 16, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Christoph Hoenke, Thomas Trieselmann, Patrick Tielmann, Stefan Scheuerer, Silke Hobbie, Frank Buettner
  • CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD
    Publication number: 20130324517
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: July 24, 2013
    Publication date: December 5, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heiner EBEL, Sara FRATTINI, Riccardo GIOVANNINI, Christoph HOENKE, Thomas TRIESELMANN, Patrick TIELMANN, Stefan SCHEUERER, Silke HOBBIE, Frank BUETTNER
  • CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD
    Publication number: 20120053164
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, ?CH—, —CH2—, —O—, —S—, and —NH—; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.
    Type: Application
    Filed: December 17, 2009
    Publication date: March 1, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Christoph Hoenke, Thomas Trieselmann, Patrick Tielmann, Stefan Scheuerer, Silke Hobbie, Frank Buettner
  • Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
    Publication number: 20100197908
    Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: December 10, 2007
    Publication date: August 5, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Dirk Stenkamp, Gerald Juergen Roth, Stephan Georg Mueller, Joerg Kley, Armin Heckel, Klaus Rudolf, Marcus Schindler, Ralf Lotz, Patrick Tielmann
  • High-throughput screening method for determining the enantioselectivity of catalysts, biocatalysts, and agents
    Publication number: 20050153358
    Abstract: The invention relates to a high-throughput screening method based on NMR spectroscopy for determining the enantioselectivity of reactions which show an asymmetric course. The reactions can be caused by chiral catalysts, agents, or biocatalysts such that said products can be evaluated regarding the enantioselectivity thereof. In one embodiment, isotope-marked pseudo-enantiomers or pseudo-prochiral substrates are used such that the enantioselectivity can be quantified by integrating the NMR signals of the respective substrates and/or products. The use of an automated setup of devices, including microtiter plates, robots, and high-throughput NMR devices, is decisive for the high-throughput process. In a second embodiment of the invention, the automated setup of devices is used to detect in a quantitative manner the products and/or educts that have been derivatized with enantiomer-pure agents in the form of diastereomers.
    Type: Application
    Filed: February 22, 2003
    Publication date: July 14, 2005
    Applicant: Studiengesellschaft Kohle mbH
    Inventors: Manfred Reetz, Patrick Tielmann, Andreas Eipper, Richard Mynott